Last $4.60 USD
Change Today -0.09 / -1.92%
Volume 246.4K
XNPT On Other Exchanges
As of 3:49 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $7.20
52 Week Low
05/9/14 - $3.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. It markets HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome, as well as for the management of postherpetic neuralgia in adults in the United States. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is being studied in a Phase I clinical trial for the treatment of psoriasis and/or relapsing forms of multiple sclerosis. In addition, it is developing product candidates that have completed Phase II clinical trial, including arbaclofen placarbil, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

92 Employees
Last Reported Date: 02/28/14
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $369.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $426.4K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $353.9K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $336.0K
Compensation as of Fiscal Year 2013.

xenoport inc (XNPT) Key Developments

XenoPort, Inc. Announces Initiation of Phase 2 Clinical Trial of XP23829 in Patients With Psoriasis

XenoPort, Inc. announced that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis. XenoPort expects to enroll approximately 200 subjects in this trial, which is being conducted in the United States. The study will include a screening and washout phase of up to four weeks, a 12-week treatment phase and a four-week post-treatment phase. Eligible study subjects will be randomized to placebo or one of three treatment arms of XP23829: 400 mg or 800 mg once daily or 400 mg twice daily. The primary endpoint of the study will examine the percent change in Psoriasis Area and Severity Index (PASI) score from baseline at the end of week 12. Secondary endpoints will include the proportion of subjects who achieve a reduction of 75% or greater from baseline in PASI (PASI-75) score and subjects who achieve a Static Physicians Global Assessment (sPGA) score of clear or almost clear.

Xenoport, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:30 PM

Xenoport, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.

Reckitt Benckiser Pharmaceuticals and XenoPort Enter into Global Licensing Agreement for Arbaclofen Placarbil

Reckitt Benckiser Pharmaceuticals Inc. and XenoPort, Inc. announced that they have entered into a license agreement pursuant to which Reckitt Benckiser Pharmaceuticals will be granted exclusive worldwide rights for the development and commercialization of XenoPort's clinical-stage oral product candidate arbaclofen placarbil for all indications. Arbaclofen placarbil is a patent protected new chemical entity that Reckitt Benckiser Pharmaceuticals plans to advance into a Phase IIB proof-of-concept study for the treatment of alcohol use disorders - a condition affecting more than 140 million people worldwide. Alcohol use disorders are a global public health issue, with an annual economic burden of $224 billion in the United States alone. Alcoholism is directly responsible for more than 2.5 million deaths each year and is a causal factor in over 60 other major types of disease. The current treatment approach is predominantly psychosocial support and is largely non-medicalized. The majority of healthcare professionals feel underequipped to manage patients with substance abuse - including alcoholism - based on currently available standards of care.Arbaclofen placarbil will be tested for its ability to suppress alcohol cravings, reduce alcohol intake and to possibly facilitate maintenance of abstinence in alcohol dependent people. In prior clinical trials, arbaclofen placarbil has demonstrated attributes that may enable convenient dosing, stable plasma exposure and good tolerability. Under the terms of the agreement, Reckitt Benckiser Pharmaceuticals will receive exclusive rights to develop and commercialize arbaclofen placarbil worldwide for all indications, subject to certain rights by XenoPort to negotiate with Reckitt Benckiser Pharmaceuticals on collaborations for non-addiction indications. In exchange for these rights and upon effectiveness of the agreement, XenoPort is entitled to receive an up-front, non-refundable cash payment of $20 million and another $5 million upon the transfer of certain technology and materials to Reckitt Benckiser Pharmaceuticals. XenoPort also will be eligible to receive aggregate cash payments of up to $70 million upon the achievement by Reckitt Benckiser Pharmaceuticals of certain development and regulatory milestones, as well as up to $50 million for commercial milestones. In addition, XenoPort is entitled to receive tiered double-digit royalty payments up to the mid-teens on a percentage basis on potential future net sales of arbaclofen placarbil in the United States and high single-digit royalty payments on potential future net sales outside the United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $4.61 USD -0.08

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Access Pharmaceuticals Inc $0.26 USD -0.011
BioDelivery Sciences International Inc $14.08 USD +0.64
Depomed Inc $12.95 USD -0.45
Flamel Technologies SA $14.90 USD +0.03
Merrion Pharmaceuticals Plc €0.50 EUR -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.6x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at